Early results from the company’s single-arm trial saw the therapy able to partially repair the chemical responsible for ...

present an important study that applied a high-resolution transposon-based barcoding system to show the clonal contribution of hematopoietic stem and ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to EXG-34217 for the treatment of telomere biology disorders.

Data published in NEJM Evidence detail the first clinical test of ZSCAN4 for telomere elongation.Treatment with EXG-34217 resulted in in vivo ...

Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation. Leukemia. 2025;1-11.

在传统认知中，骨髓衰竭往往意味着造血功能不可逆转的衰退。但最新临床实践表明，当脐带血治疗突破单兵作战模式，与靶向药物、免疫调节形成组合拳时，其修复效能可提升3-5倍。这种转变源于对造血微环境的深层认知：放疗化疗不仅摧毁造血干细胞，更破坏骨髓中的支持细胞网络。65岁王女士的治疗案例印证了这点——在脐带血输注后，其骨髓基质细胞分泌的SCF因子浓度提升4.2倍，这正是血小板回升的关键信号。

为探究高原动物心脏适应机制，研究人员开展牦牛心脏中 Telocytes（TCs）的研究。结果发现其在主动脉球和心肌的分布、特征等。该研究为揭示高原动物适应环境的奥秘提供关键线索，值得科研读者一读。

为解决糖尿病足溃疡（DFU）治疗难题，苏州大学第一附属医院的研究人员开展 ANG1 改造间充质干细胞（MSCs）的研究，发现其能促进血管生成和伤口愈合。该研究为 DFU 治疗提供新策略，值得科研读者一读。

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

急性髓系白血病（AML）是一种常见的造血系统恶性肿瘤，其特征为未成熟白血病细胞在骨髓中的过度增殖，并伴随正常血细胞生成受阻。尽管近年来AML的治疗有所进展，但由于其高度异质性、疗效有限以及高复发率，AML患者的五年生存率依然较低。AML的病理机制研究 ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...